217 related articles for article (PubMed ID: 16524973)
21. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.
Swisher SG; Moughan J; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
J Thorac Oncol; 2017 Feb; 12(2):368-374. PubMed ID: 27729298
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
23. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
[TBL] [Abstract][Full Text] [Related]
24. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
Burmeister BH; Denham JW; O'Brien M; Jamieson GG; Gill PG; Devitt P; Yeoh E; Hamilton CS; Ackland SP; Lamb DS
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):997-1006. PubMed ID: 7607974
[TBL] [Abstract][Full Text] [Related]
25. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).
Ruhstaller T; Templeton A; Ribi K; Schuller JC; Borner M; Thierstein S; von Moos R; Pederiva S; Lohri A; Lombriser N; von Briel C; Koeberle D; Popescu R
Onkologie; 2010; 33(5):222-8. PubMed ID: 20502056
[TBL] [Abstract][Full Text] [Related]
26. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
Algan O; Coia LR; Keller SM; Engstrom PF; Weiner LM; Schultheiss TE; Hanks GE
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):753-61. PubMed ID: 7790262
[TBL] [Abstract][Full Text] [Related]
27. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.
Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M
Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant (postoperative) therapy for esophageal cancer.
Ku GY; Ilson DH
Thorac Surg Clin; 2013 Nov; 23(4):525-33. PubMed ID: 24199702
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
[TBL] [Abstract][Full Text] [Related]
31. Resectability rates in locally advanced esophageal carcinoma following neo-adjuvant chemoradiotherapy.
Abbas A; Ali N; Hameed S; Shah MA
J Ayub Med Coll Abbottabad; 2003; 15(4):13-6. PubMed ID: 15067824
[TBL] [Abstract][Full Text] [Related]
32. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus.
Forastiere AA; Heitmiller RF; Lee DJ; Zahurak M; Abrams R; Kleinberg L; Watkins S; Yeo CJ; Lillemoe KD; Sitzmann JV; Sharfman W
Cancer J Sci Am; 1997; 3(3):144-52. PubMed ID: 9161779
[TBL] [Abstract][Full Text] [Related]
33. Does neoadjuvant treatment before oncologic esophagectomy affect the postoperative quality of life? A prospective, longitudinal outcome study.
Hauser C; Patett C; von Schoenfels W; Heits N; Schafmayer C; Malchow B; Hampe J; Schniewind B; Becker T; Egberts JH
Dis Esophagus; 2015 Oct; 28(7):652-9. PubMed ID: 25059631
[TBL] [Abstract][Full Text] [Related]
34. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Elsaleh H; Farrell JJ; Crane CH
J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
[No Abstract] [Full Text] [Related]
35. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
[TBL] [Abstract][Full Text] [Related]
36. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Goldberg M; Farma J; Lampert C; Colarusso P; Coia L; Frucht H; Goosenberg E; Beard M; Weiner LM
J Thorac Cardiovasc Surg; 2003 Oct; 126(4):1168-73. PubMed ID: 14566264
[TBL] [Abstract][Full Text] [Related]
37. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Kleinberg L; Knisely JP; Heitmiller R; Zahurak M; Salem R; Burtness B; Heath EI; Forastiere AA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):328-34. PubMed ID: 12738305
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
[TBL] [Abstract][Full Text] [Related]
39. Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990.
Kavanagh B; Anscher M; Leopold K; Deutsch M; Gaydica E; Dodge R; Allen K; Allen D; Staub W; Montana G
Int J Radiat Oncol Biol Phys; 1992; 24(4):633-42. PubMed ID: 1429085
[TBL] [Abstract][Full Text] [Related]
40. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
